Five‐year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial
International Journal of Cancer · 2024-10 · 155 (7) · 1248-1256
DOI: 10.1002/ijc.35052 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, online erschienen am 19.06.2024. Verfasst von Andrew W See und 13 weiteren Autor:innen. Beteiligte Einrichtung: Icon Cancer Centre, Richmond, Victoria, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiosurgery. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Epworth Medical Foundation, E.J. Whitten Foundation Prostate Cancer Research Centre at Epworth HealthCare, Varian, a Siemens Healthineers company.
Abstract (Originalsprache)
Metastasis‐directed therapy (MDT) for oligometastatic prostate cancer (PCa), including stereotactic body radiotherapy (SBRT), has shown promise but is still considered investigational. This is the 5‐year analysis of the TRANSFORM trial, the largest prospective cohort of men with oligometastatic PCa treated with SBRT‐based MDT. The primary endpoint was 5‐year treatment escalation‐free survival (TE‐FS), defined as freedom from any new cancer therapy other than further SBRT. In total, 199 men received SBRT; 76.4% were hormone‐naïve at baseline. The rate of 5‐year TE‐FS was 21.7% (95% confidence interval [CI]: 15.7%–28.7%) overall and 25.4% (95% CI: 18.1%–33.9%) in the hormone‐naïve subgroup. The subgroups with International Society of Urological Pathology Grade Groups 4–5 disease (hazard ratio [HR] = 1.48, 95% CI: 1.05–2.01, p = .026), a higher baseline prostate‐specific antigen (PSA) (HR = 1.06, 95% CI: 1.03–1.09, p < .001) and those who received prior androgen deprivation therapy (ADT) (HR = 2.13, 95% CI: 1.40–3.26, p < .001), were at greater risk of treatment escalation. Outcomes for participants with four or five initial lesions were comparable to those with one to three lesions. At last follow‐up, 18.9% (95% CI: 13.2%–25.7%) of participants were free from treatment escalation (median follow‐up of 67.9 months) and two participants had an undetectable PSA level. No treatment‐related grade three or higher adverse events were reported. The findings of this study demonstrate that SBRT‐based MDT is an effective option for delaying systemic treatment escalation in the context of oligometastatic PCa. Future randomised trials comparing SBRT‐based MDT to standard‐of‐care ADT‐based approaches are required to evaluate the impact of delaying ADT on survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Icon Cancer Centre, Richmond, Victoria, Australia.
- Department of Surgery, Monash University, Melbourne, Victoria, Australia.
- Australian Urology Associates, Melbourne, Victoria, Australia.
- Department of Urology, The Canberra Hospital, Canberra, Australian Capital Territory, Australia.
- College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory, Australia.
- Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.
ORCID-Profile: Lloyd M L Smyth, Patrick Bowden
Förderung
- Epworth Medical Foundation
- E.J. Whitten Foundation Prostate Cancer Research Centre at Epworth HealthCare
- Varian, a Siemens Healthineers company
- Icon Cancer Foundation
- Varian Medical Systems
Zitieren
APA
See, A. W., Conway, P., Frydenberg, M., Haxhimolla, H., Costello, A. J., Moon, D., Ruljancich, P., Grummet, J., Pranavan, G., Peters, J., Smyth, L. M. L., Gwini, S. M., McKenzie, D. P., & Bowden, P. (2024). Five‐year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial. International Journal of Cancer, 155(7), 1248-1256. https://doi.org/10.1002/ijc.35052
Vancouver
See AW, Conway P, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, et al. Five‐year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial. International Journal of Cancer. 2024;155(7):1248-1256. doi:10.1002/ijc.35052
BibTeX
@article{See2024,
author = {See, Andrew W and Conway, Paul and Frydenberg, Mark and Haxhimolla, Hodo and Costello, Anthony J and Moon, Daniel and Ruljancich, Paul and Grummet, Jeremy and Pranavan, Ganes and Peters, Justin and Smyth, Lloyd M L and Gwini, Stella M and McKenzie, Dean P and Bowden, Patrick},
title = {Five‐year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial},
journal = {International Journal of Cancer},
year = {2024},
volume = {155},
number = {7},
pages = {1248--1256},
doi = {10.1002/ijc.35052}
}
EUVIMED